Research location

Shantou

Guangdong, China

Published trials79

Site observations81

Linked trials published79

Page1 / 2

Research activity in Shantou

Guangdong, China

CureCurrent currently publishes aggregate city-level research activity for this location: 79 trials and 81 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Shantou

79 linked trials · page 1 of 2

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseNCT07492641 · 2026-05-22 · 1 site observation

A Phase II Trial of G01 Eye Drops for Glaucomatous Optic NeuropathyNCT07777861 · 2026-03-18 · 1 site observation

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)NCT07361497 · 2026-03-16 · 1 site observation

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)NCT07361510 · 2026-03-12 · 1 site observation

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsNCT07185997 · 2025-12-17 · 1 site observation

A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib MonotherapyNCT07375316 · 2025-12-15 · 1 site observation

Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid TumorsNCT07071103 · 2025-09-26 · 1 site observation

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CancerNCT07043725 · 2025-09-15 · 1 site observation

Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast CancerNCT07095023 · 2025-08-15 · 1 site observation

A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast CancerNCT07003074 · 2025-06-23 · 1 site observation

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)NCT06952504 · 2025-05-22 · 1 site observation

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)NCT06875310 · 2025-04-24 · 1 site observation

Development of an AI-Agent for Urological Disease Diagnosis and TreatmentNCT07721935 · 2025-04-01 · 1 site observation

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).NCT06646276 · 2025-02-25 · 1 site observation

A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Breast Cancer PatientsNCT06811870 · 2025-02-01 · 1 site observation

A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast CancerNCT07673029 · 2025-01-10 · 1 site observation

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.NCT06629779 · 2024-10-22 · 1 site observation

Methotrexate Combined With Tofacitinib in Rheumatoid ArthritisNCT06301373 · 2024-09-01 · 1 site observation

Long-Term Outcomes of Endoscopic-assisted vs Conventional Breast-conserving Surgery in Breast Cancer Patients After Neoadjuvant Therapy: a Randomized, Multicenter, Open Label, Non-inferiority TrialNCT06716073 · 2024-08-01 · 1 site observation

A Study of YL202 in Selected Patients With Advanced Solid TumorsNCT06107686 · 2023-12-15 · 1 site observation

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)NCT05920356 · 2023-11-16 · 1 site observation

Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)NCT05904964 · 2023-07-01 · 1 site observation

Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression PatternsNCT06551220 · 2022-10-10 · 1 site observation

Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRDNCT05457049 · 2022-08-01 · 2 site observations

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT04928846 · 2022-03-25 · 1 site observation

Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation IndexNCT05728268 · 2021-08-01 · 1 site observation

Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast CancerNCT04263298 · 2018-05-01 · 1 site observation

DIEP-MDS for Risk Stratification of Flap Vascular Compromise and Failure in Breast ReconstructionNCT07761390 · 2026-01-01 · 1 site observation

ACTIVE_NOT_RECRUITING

To Evaluate the Efficacy and Safety of the Insulin Patch Pump System in Patients With Diabetes.NCT07403565 · 2025-06-14 · 1 site observation

Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung CancerNCT06897579 · 2025-04-07 · 1 site observation

Effect of Infusion Warming on Mannitol Infusion Pain in Patients With Acute Ocular HypertensionNCT07495449 · 2025-01-09 · 1 site observation

Airwave Compression Therapy to Prevent Breast Cancer-related LymphedemaNCT06495034 · 2023-07-01 · 1 site observation

Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.NCT05922345 · 2023-06-08 · 1 site observation

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and InflammationNCT05636176 · 2023-05-08 · 1 site observation

FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast CancerNCT05755048 · 2023-03-28 · 1 site observation

Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLCNCT05765825 · 2023-03-07 · 1 site observation

ACTIVE_NOT_RECRUITING

Effect of Intensive FMT on Primary HypertensionNCT05608447 · 2023-01-01 · 1 site observation

Nursing Intervention Based on Stress Adaptation Theory for Patients Undergoing Diabetic Retinal Laser SurgeryNCT07544381 · 2022-10-01 · 1 site observation

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung CancerNCT05042375 · 2022-09-08 · 1 site observation

A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid ArthritisNCT05516758 · 2022-08-31 · 1 site observation

A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast CancerNCT05433480 · 2022-05-25 · 1 site observation

A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast CancerNCT05346224 · 2022-04-25 · 2 site observations

ACTIVE_NOT_RECRUITING

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)NCT05239741 · 2022-04-02 · 1 site observation

ACTIVE_NOT_RECRUITING

China Research of IDEgAsp Treatment in Real-world Clinical practicE (CREATE)NCT05221580 · 2022-03-18 · 1 site observation

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)NCT05173987 · 2022-02-03 · 1 site observation

ACTIVE_NOT_RECRUITING

Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT04921358 · 2021-07-27 · 1 site observation

Effect of Gut Microbiome Restoration on Primary Hypertension Via Dietary InterventionNCT04403347 · 2021-07-08 · 1 site observation

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung CancerNCT04746924 · 2021-05-24 · 1 site observation

Effect of Gut Microbiome Restoration on Primary Hypertension Via FMTNCT04406129 · 2021-03-17 · 1 site observation

Serum and Tissue Metabolite-based Prediction of Sentinel Lymph Node Metastasis in Breast CancerNCT06001528 · 2021-01-01 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.